Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495

Neuropharmacology

Volumn 57, Issue 2, 2009, Pages 172-182

  Linden, A M ^a   Johnson, B G ^b   Trokovic, Nina ^a   Korpi, E R ^a   Schoepp, D D ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

c Fos; Central nucleus of the amygdala; Knockout; Locomotor activity; Metabotropic glutamate receptor 2 3 antagonist; Ventrolateral nucleus of the thalamus

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; DRUG SPECIFICITY; EMBRYO; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; STRAIN DIFFERENCE; STRIA TERMINALIS; THALAMUS VENTRAL NUCLEUS; WILD TYPE;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HABITUATION, PSYCHOPHYSIOLOGIC; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MICE; MICE, KNOCKOUT; PHOTOMICROGRAPHY; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, METABOTROPIC GLUTAMATE; XANTHENES;

EID: 67650167698     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.05.002     Document Type: Article

References (41)

1. Alexander G.M., and Godwin D.W. Unique presynaptic and postsynaptic roles of group II metabotropic glutamate receptors in the modulation of thalamic network activity. Neuroscience 141 (2006) 501-513
2. Alexander G.M., and Godwin D.W. Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. Journal of Neurophysiology 94 (2005) 163-175
3. Bespalov A., Jongen-Relo A.L., van Gaalen M., Harich S., Schoemaker H., and Gross G. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: Reversal by antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 944-950
4. Bespalov A.Y., van Gaalen M.M., Sukhotina I.A., Wicke K., Mezler M., Schoemaker H., and Gross G. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. European Journal of Pharmacology 592 (2008) 96-102
5. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., Yoshimizu T., Yasuhara A., Sakagami K., Okuyama S., Nakanishi S., and Nakazato A. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46 (2004) 457-467
6. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., Mugnaini M., Nicoletti F., and Bruno V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. Journal of Neuroscience 27 (2007) 8297-8308
7. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., and Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33 (2008) 1603-1610
8. Elble R. Animal models of action tremor. Movement Disorders 13 (1998) 35-39
9. Feinberg I., Schoepp D.D., Hsieh K.C., Darchia N., and Campbell I.G. The metabotropic glutamate (mGlu)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGlu2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 826-833
10. Fell M.J., Johnson B.G., Svensson K.A., and Schoepp D.D. Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. Journal of Pharmacology and Experimental Therapeutics 326 (2008) 209-217
11. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press Inc, San Diego
12. Gu G., Lorrain D.S., Wei H., Cole R.L., Zhang X., Daggett L.P., Schaffhauser H.J., Bristow L.J., and Lechner S.M. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition. Brain Research 1197 (2008) 47-62
13. Hetzenauer A., Corti C., Herdy S., Corsi M., Ferraguti F., and Singewald N. Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-fos expression pattern evoked by mGlu2/3 antagonism. Psychopharmacology 201 (2008) 1-13
14. Higgins G.A., Ballard T.M., Kew J.N., Richards J.G., Kemp J.A., Adam G., Woltering T., Nakanishi S., and Mutel V. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46 (2004) 907-917
15. Iijima M., Shimazaki T., Ito A., and Chaki S. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology 190 (2007) 233-239
16. Johnson B., Wright R., Arnold M., Wheeler W., Ornstein P., and Schoepp D.D. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology 38 (1999) 1519-1529
17. Kingston A., Ornstein P., Wright R., Johnson B., Mayne N., Burnett J., Belagaje R., Wu S., and Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37 (1998) 1-12
18. Linden A.M., Baez M., Bergeron M., and Schoepp D.D. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus. Neuropharmacology 51 (2006) 213-228
19. Linden A.M., Bergeron M., and Schoepp D.D. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: Evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology 49 (2005) 120-134
20. Linden A.M., and Schoepp D.D. Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discovery Today: Therapeutic Strategies 3 (2006) 507-517
21. Linden A.M., Shannon H., Baez M., Yu J.L., Koester A., and Schoepp D.D. Anxiolytic-like activity of the mGlu2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knockout mice. Psychopharmacology (Berl) 179 (2005) 284-291
22. Lyon L., Kew J.N., Corti C., Harrison P.J., and Burnet P.W. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse 62 (2008) 842-850
23. Miwa H., Nishi K., Fuwa T., and Mizuno Y. Differential expression of c-Fos following administration of two tremorgenic agents: harmaline and oxotremorine. Neuroreport 11 (2000) 2385-2390
24. Morishima Y., Miyakawa T., Furuyashiki T., Tanaka Y., Mizuma H., and Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proceedings of the National Academic Sciences USA 102 (2005) 4170-4175
25. Muly E.C., Mania I., Guo J.D., and Rainnie D.G. Group II metabotropic glutamate receptors in anxiety circuitry: correspondence of physiological response and subcellular distribution. Journal of Comparative Neurology 505 (2007) 682-700
26. Ngomba R.T., Biagioni F., Casciato S., Willems-van Bree E., Battaglia G., Bruno V., Nicoletti F., and van Luijtelaar E.L. The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike-wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology 1 (2005) 89-103
27. Ohishi H., Shigemoto R., Nakanishi S., and Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. Journal of Comparative Neurology 335 (1993) 252-266
28. O'Neill M.F., Heron-Maxwell C., Conway M.W., Monn J.A., and Ornstein P. Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45 (2003) 565-574
29. Ornstein P., Bleisch T., Arnold M., Kennedy J.H., Wright R.A., Johnson B.G., Tizzano J.P., Helton D.R., Kallman M.J., and Schoepp D.D. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. Journal of Medicinal Chemistry 41 (1998) 358-378
30. Patil S.T., Zhang L., Martenyi F., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nature Medicine 13 (2007) 1102-1107
31. Pilc A., Chaki S., Nowak G., and Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochemical Pharmacology 75 (2008) 997-1006
32. Salt T.E., and Turner J.P. Modulation of sensory inhibition in the ventrobasal thalamus via activation of group II metabotropic glutamate receptors by 2R,4R-aminopyrrolidine-2,4-dicarboxylate. Experimental Brain Research 121 (1998) 181-185
33. Shimazaki T., Iijima M., and Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. European Journal of Pharmacology 501 (2004) 121-125
34. Shimazaki T., Kaku A., and Chaki S. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. European Journal of Pharmacology 575 (2007) 94-97
35. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Review Drug Discovery 4 (2005) 131-144
36. Tamaru Y., Nomura S., Mizuno N., and Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106 (2001) 481-503
37. Woolley M.L., Pemberton D.J., Bate S., Corti C., and Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196 (2008) 431-440
38. Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., and Schoepp D.D. Binding of 3H-(2S,1'S2'S)-2-(9-xanthylmethyl)-2-(2'carboxycyclopropyl)glycine (3H-LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology 362 (2000) 546-554
39. Yilmazer-Hanke D.M. Morphological correlations of emotional and cognitive behaviour: insights from studies on inbred and outbred rodent strains and their crosses. Behavioural Pharmacology 19 (2008) 403-434
40. Yokoi M., Kobayashi K., Manabe T., et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 273 (1996) 645-647
41. Yoshimizu T., Shimazaki T., Ito A., and Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186 (2006) 587-593